Kraft Heinz Announces Major Change To All Of Their Products Coming Soon
Changes are coming to your favorite Kraft Heinz products. The food company announced Tuesday it will no longer launch any new food products in the U.S. that contain Food, Drug & Cosmetic (FD&C) colors. The company will also remove synthetic colors from all of its existing U.S. products by the end of 2027.
'The vast majority of our products use natural or no colors, and we've been on a journey to reduce our use of FD&C colors across the remainder of our portfolio,' says Pedro Navio, North America President at Kraft Heinz.
Nearly 90 percent of its U.S. products are already free of FD&C colors. The company removed artificial colors, flavors, and preservatives from its popular Kraft Mac and Cheese in 2016, and its Heinz Tomato Ketchup has never contained artificial dyes.
The company says it will remove colors from any products where their absence will not affect consumer experience, replace artificial colors with natural colors, or create new colors when a natural replacement isn't available. Since dyes are used to enhance the color of foods, their removal will not affect the taste of your favorite products.
'Above all, we are focused on providing nutritious, affordable, and great-tasting food for Americans and this is a privilege we don't take lightly,' Navio says.
FD&C colors such as Blue No. 1, Yellow No. 5, and Red No. 3 are synthetic color additives approved by the Food and Drug Administration (FDA) to create consistent, vibrant colors in food, drug, and cosmetic products. The FDA revoked the use of Red No. 3 in food and ingested drugs in January, phasing out its use by January 15, 2027. In April, Health and Human Services Secretary Robert F. Kennedy Jr. called for the removal of artificial dyes in U.S. foods.
Kraft Heinz says it is continually evolving its recipes and product line to improve nutritional profiles, such as reducing sugar, salt, and saturated fat in more than 1,000 products. It is also encouraging licensees of its brands to remove artificial colors from their products as well. In addition to Kraft and Heinz, the company owns a variety of brands including Jell-O, Oscar Mayer, Philadelphia, Capri Sun, Kool-Aid, Lunchables, and more.
Read the original article on Southern Living
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
6 minutes ago
- Medscape
Heat, Poor Air Quality Ups Heart Attack Risk
Simultaneous exposure to ozone pollution and high temperatures significantly increases the risk for acute myocardial infarction (MI) among adults in the US, according to a recent study published in Circulation . The findings highlight the dangers of joint environmental stressors even at moderate levels and the importance of timely patient counseling. Using nationwide private insurance claims data from 2016 to 2020, researchers from Yale School of Public Health, New Haven, Connecticut, and collaborators identified 270,123 cases of acute MI in people aged 18-64 years. They found joint exposure to ground-level ozone (60 ppb) and high temperatures — roughly 90-95 °F — increased the risk for an MI by 33% compared to cooler, low-ozone days. Even under moderate conditions, such as an ozone count of 50 ppb and typical temperatures around 70 °F, the risk increased by 15%. 'The lag 0f effect means clinicians need to pay close attention to high-pollution and hot days in real time,' said Lingzhi Chu, PhD, a postdoctoral associate in the Department of Environmental Health Sciences at the Yale School of Public Health and colead author of the study 'Clinicians should emphasize to younger patients that moderate levels still pose risks' to cardiovascular health. Mary Johnson, PhD, a principal research scientist of environmental health at the Harvard T.H. Chan School of Public Health in Boston, said the findings bring much-needed attention to a younger demographic. 'This study is important because it focuses on a younger age group that is often overlooked in cardiovascular research,' said Johnson, who was not involved in the study. 'Typically, you don't think about heart attacks happening in people in the young adult category.' Johnson also noted the value of examining heat and ozone together. 'We've seen studies showing impacts from temperature and from ozone individually,' she said, 'but looking at them together, and especially looking at differences between men and women, is important.' Different Risks by Sex According to the study, women showed increased vulnerability on days with both high ozone and temperatures around 90-95 degrees, while men experienced heightened risk even when only one factor was elevated. The difference in exposure-response patterns by sex was statistically significant ( P = .016). Chu said clinicians should tailor counseling based on patient demographics. 'The sex difference that males are vulnerable to mild exposures is critical,' Chu said. 'Young men need targeted proactive counselling.' While the researchers did not assess comorbidities like hypertension or diabetes, Chu acknowledged these conditions could affect risk. 'The potential pathophysiology suggests hypertension, diabetes, or obesity may compound risks, but further research is warranted,' Chu said. Johnson said these findings should challenge assumptions in primary care because these clinicians often are the first to encounter patients of the age group studied. 'Just because you're young and healthy does not necessarily rule out the risk of a cardiac event,' she said. 'Especially if there's a combination of poor air quality and elevated temperature.' Communicating Practical Prevention Acute MI is a leading cause of morbidity and mortality globally, with approximately 800,000 cases annually in the US. Adults younger than 55 years, and particularly women, account for a growing share of acute MIs. Chu recommended several practical prevention strategies clinicians can share with patients: Adjusting the timing of outdoor activities, staying hydrated, and using cooling methods such as fans or air conditioning. She also acknowledged the challenge clinicians face in educating patients without overwhelming them. 'Clinicians may consider framing mitigation as simple behavior changes rather than drastic life changes to prevent patient overwhelm,' she said. 'Some of these simple changes — like checking air quality apps, closing windows on high-ozone days, or staying hydrated — support overall health, not just cardiovascular health.' Johnson agreed. 'While we can't individually control wildfires or ozone formation, everyone can be aware of ozone levels and temperature before going outside or doing anything physically strenuous,' she said. Health Equity Concern The study relied on data from individuals with private insurance, a limitation both Chu and Johnson acknowledged. 'That population has access to care,' Johnson said. 'But what about the uninsured or underinsured? They may be more at risk because they often live in areas with worse air quality and lack resources to adapt, like access to cooling systems or healthcare.' She added that events like sudden cardiac death may be underreported in uninsured populations. 'They don't go to the emergency room. They die before they get there,' Johnson said. 'So the real risk may actually be higher than what this study captured.' Johnson said the findings also highlight a critical shift in how clinicians should view environmental risk. 'It's accurate to say we can no longer think about air pollution and environmental risks as being linked only to chronic conditions,' said Johnson. 'There are acute consequences, too, and this study illustrates that clearly.' A study published last month in the journal Epidemiology found prolonged exposure to the particulate matter in wildfire smoke was associated with small increases in the risk for several cardiovascular diseases, especially hypertension. As climate change drives more frequent heat waves and worsens air quality, both Chu and Johnson said clinicians are on the front lines of patient education and prevention. 'Clinicians are key players in translating environmental health research into actionable prevention,' Chu said. 'This study reinforces the need to think beyond traditional risk factors.' Chu and Johnson reported no relevant financial conflicts of interest.
Medscape
30 minutes ago
- Medscape
Next-Generation Obesity Treatments Take Center Stage at ADA
The upcoming American Diabetes Association (ADA) 85th Scientific Sessions will focus on new and evolving weight-loss treatments for people with and without diabetes, along with new biological and technological approaches for managing type 1 diabetes (T1D). Late-breaking symposia will include data from trials of a once-monthly injectable for obesity treatment, a nonpeptide oral GLP-1 receptor agonist (RA), and a medication combining a GLP-1 RA with another drug designed to augment fat loss while preserving lean mass. Other new findings at the meeting include the use of a GLP-1 RA in T1D and the latest data on stem cell-derived islet cell transplantation in T1D. And always, there's much more. The meeting will take place from June 20 to 24, 2025, in Chicago. 'This year again, it will be heavily focused on obesity but more on the next generation of obesity drugs. We're progressing to therapy that may be more amenable to the patient, with less frequent dosing and greater convenience,' Marlon Pragnell, PhD, ADA's vice president of research and science, told Medscape Medical News . A major theme of the meeting, said Conference Planning Committee Chair Mark A. Atkinson, PhD, director of the University of Florida Diabetes Institute, Gainesville, Florida, will be 'after decades of making moderate impacts on both type 1 and type 2 diabetes, we are now in a position where we're moving from baby steps to big leaps, be it through technology, as well as new drugs for type 2 diabetes (T2D) and obesity. There's a very positive evolution here, but now that we have all these new tools, how do we most effectively use them?' And of course, the 'elephant in the room,' Atkinson noted, is the cost of the new approaches and access, another topic that will be addressed in several sessions. 'Cost is also a huge factor. There will be discussions about cost and cost effectiveness.' Late-breaking symposia topics include the following: Once-monthly maridebart cafraglutide (MariTide, Amgen) for the treatment of obesity in people with or without T2D — a 52-week phase 2 study : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. First report of a phase 3 radomized controlled trial of orforglipron, a small nonpeptide GLP-1 RA, as monotherapy in drug-naïve T2D with inadequate glycemic control — the ACHIEVE-1 trial: These will be the full data for Eli Lilly's investigational product, following the release of top-line results in April 2025. The potential advantages here are not just that it would be an oral GLP-1 RA but because it's a nonpeptide small molecule it could be taken regardless of food or liquid intake, it wouldn't require refrigeration, and could potentially be manufactured more cheaply than injected GLP-1 RAs. 'This is actually very exciting,' Pragnell commented. Can we improve the quality of weight loss by augmenting fat mass loss while preserving lean mass? The BELIEVE study of bimagrumab plus semaglutide: The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. Efficacy and safety of CagriSema 2.4 mg/2.4 mg in adults with overweight/obesity — the REDEFINE 1 and REDEFINE 2 clinical trials: Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. ADJUnct semaglutide treatment in T1D (ADJUST-T1D) trial outcomes: With obesity increasingly recognized as an issue in T1D, the ADJUnct study examined the impact of adding semaglutide to automated insulin delivery. This symposium will include new trial outcomes. Other late-breaking symposia will cover results of the CATALYST trial of treatment of hypercortisolism in difficult to control T2D, new data from the STRIDE trial of semaglutide in peripheral artery disease, and the full data for the SOUL trial of oral semaglutide (Rybelsus) on cardiovascular and other outcomes in people with T2D at high cardiovascular risk. And there's much more, including results from a trial called PATHWEIGH, focusing on weight management in primary care, updates on inhaled insulin, new data on Vertex's stem cell-derived transplanted islets in T1D, and the use of artificial intelligence in diabetes management. According to Atkinson, 'This year's scientific sessions will showcase cutting-edge advancements in diabetes research through a robust, data-focused program. Whether attending in person or watching on-demand, participants will have the chance to connect with top experts, take part in engaging discussions, and gain critical insights that will help shape the future of diabetes care.' Pregnall and Atkinson had no disclosures.
Yahoo
31 minutes ago
- Yahoo
Greybox Solutions Deploys TakeCare(TM) Digital Health Platform in Quebec-Secured by Quantum eMotion's Advanced Cybersecurity Technology
Montreal, Quebec--(Newsfile Corp. - June 18, 2025) - Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) ("QeM" or the "Company") is pleased to announce that its partner, Greybox Solutions, has begun deploying its secure digital health platform, TakeCareTM, across leading rehabilitation centers in Quebec. Developed in collaboration with McGill University and Université de Montréal, TakeCareTM, is being implemented as part of the $4.9 million BRILLIANT initiative, funded by the Canada Foundation for Innovation (CFI), to modernize rehabilitation services across Canada. Designed to enhance the rehabilitation process, TakeCareTM introduces intelligent digital care pathways that: Reduce intake delays Eliminate redundant clinical assessments Empower patients with real-time, digitally supported recovery plans This deployment follows the announcement of a revenue-sharing agreement between QeM and Greybox to co-secure digital health applications. As TakeCareTM scales across Canada, the integrated platform sets a new benchmark for secure, patient-centric digital therapeutics. "Securing patient data is essential to scaling digital therapeutics," said Dr. Francis Bellido, CEO of Quantum eMotion. "Our partnership with Greybox ensures that TakeCareTM not only delivers clinical innovation but also adheres to the highest standards of cybersecurity." SENTRY-Q is QeM's patented cloud-based cybersecurity solution, built around its quantum random number generation (QRNG) technology and post-quantum encryption. It addresses critical threats in telemedicine by: Ensuring data confidentiality Supporting treatment integrity Enhancing platform reliability Together, Greybox and QeM are shaping the future of digital healthcare-combining clinical excellence, system innovation, and quantum-safe security to deliver real-world impact. About Greybox Solutions Greybox Solutions is a growing Montreal-based health technology company specializing in innovative software development to improve patients' lives. Its mission is to find digital transformation solutions to address healthcare system challenges and reduce the burden of managing chronic illnesses. Greybox distributes its digital health platform, TakeCareTM to redefine the relationship between patients and their healthcare team. About QeM The Company aims to address the growing demand for affordable hardware and software security for connected devices. QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random Number Generator, a security solution that exploits the built-in unpredictability of quantum mechanics and promises to provide enhanced protection for high-value assets and critical systems. The Company intends to target highly valued Financial Services, Healthcare, Blockchain Applications, Cloud-Based IT Security Infrastructure, Classified Government Networks and Communication Systems, Secure Device Keying (IOT, Automotive, Consumer Electronics) and Quantum Cryptography. For further information, please visit our website at or contact: Francis Bellido, Chief Executive OfficerTel: 514.956.2525Email: info@ Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release may contain forward-looking statements that are subject to known and unknown risks and uncertainties that could cause actual results to vary materially from targeted results. Such risks and uncertainties include those described in the Corporation's periodic reports including the annual report or in the filings made by Quantum from time to time with securities regulatory authorities. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
